global glp-1 market size 2030 Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Weight Loss Drug Market

[DOI] [PubMed] [Google Scholar] 119.Kaestner K.H., Katz J., Liu Y., Drucker D.J., Schutz G

Additionally, evaluating how these therapies interact with current antidiabetic treatments and determining their suitability for combination therapies may further enhance their clinical value

Factors like genetics, consistency, exercise, and medical history play a role

Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)

2021Apr;70(4):698706

These medications are designed to mimic your bodys natural GLP-1, helping improve blood sugar control, facilitate weight loss, and lower cardiovascular risk factors in individuals with type 2 diabetes or obesity